Seth Harrison

Dr. Seth Harrison is founder and managing partner at ATP. He began investing in life sciences in 1991 as a venture partner at Sevin Rosen Funds and went on to be a general partner at Oak Investment Partners before starting ATP in 1999. Some of his earlier investments include Aileron Therapeutics, Akero Therapeutics, ArQule, Coelacanth, Corvidia Therapeutics, Cyrano Sciences, Gloucester Pharmaceuticals, HeartWare International, Informed Access, SGX Pharmaceuticals, Stoke Therapeutics, Syntimmune, Tendyne, Ultracision and ViroPharma. Dr. Harrison currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the 15 portfolio companies created within ATP V, ATP’s current fund, to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s health and HIV prevention.

Dr. Harrison received an A.B. from Princeton University and holds an M.D. and MBA from Columbia University. He completed a surgery internship at the Presbyterian Hospital in the City of New York.